Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

  1. ESMO
  2. Policy

Cancer Medicines Committee

The Cancer Medicines Committee (CMC) was established in 2015 to address the topics related to inexpensive and expensive cancer medicines.

Structure

The Cancer Medicines Committee is divided into two working groups:

  • Inexpensive, essential cancer medicines: The Working Group is addressing the topic of shortages of essential cancer medicines. It aims to tackle issues related to the adequate supply of inexpensive, essential cancer medicines, the lack of incentives to produce them, and the growing disparities of access to them within Europe and beyond.   
  • Expensive, innovative cancer medicines: The Working Group is addressing the issue of the sustainability of healthcare systems. It aims to work towards the development of an economic model to tackle issues related to the reimbursement of expensive, innovative medicines.

You can find out more about the work of the Cancer Medicines Committee below:

Related Links

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.